Prognostic significance of Epstein–Barr virus DNA in NK/T-cell lymphoma: a meta-analysis

References

• KwongYLNatural killer-cell malignancies: diagnosis and treatmentLeukemia200519122186219416179910
   PubMed Web of Science ®Google Scholar
• SunJYangQLuZDistribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the World Health Organization classificationAm J Clin Pathol2012138342943422912361
   PubMed Web of Science ®Google Scholar
• YangQPZhangWYYuJBSubtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institutionDiagn Pathol201167721854649
   PubMed Web of Science ®Google Scholar
• LiuJSongBFanTPathological and clinical characteristics of 1,248 non-Hodgkin’s lymphomas from a regional cancer hospital in Shandong, ChinaAsian Pac J Cancer Prev201112113055306122393989
   PubMedGoogle Scholar
• KimSJKimKKimBSPhase II trial of concurrent radiation and weekly cisplatin followed by VIPD chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell Lymphoma: Consortium for Improving Survival of Lymphoma studyJ Clin Oncol200927356027603219884539
   PubMed Web of Science ®Google Scholar
• YamaguchiMTobinaiKOguchiMPhase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan Clinical Oncology Group Study JCOG0211J Clin Oncol200927335594560019805668
   PubMed Web of Science ®Google Scholar
• KimSJYangDHKimJSConcurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II studyAnn Hematol201493111895190124947798
   PubMed Web of Science ®Google Scholar
• LeiKIChanLYChanWYJohnsonPJLoYMQuantitative analysis of circulating cell-free Epstein-Barr virus (EBV) DNA levels in patients with EBV-associated lymphoid malignanciesBr J Haematol2000111123924611091207
   PubMed Web of Science ®Google Scholar
• ChanKCZhangJChanATMolecular characterization of circulating EBV DNA in the plasma of nasopharyngeal carcinoma and lymphoma patientsCancer Res20036392028203212727814
   PubMed Web of Science ®Google Scholar
• KimuraHItoYSuzukiRNishiyamaYMeasuring Epstein-Barr virus (EBV) load: the significance and application for each EBV-associated diseaseRev Med Virol200818530531918494041
   PubMed Web of Science ®Google Scholar
• ItoYKimuraHMaedaYPretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal typeClin Cancer Res201218154183419022675173
   PubMed Web of Science ®Google Scholar
• WangZYLiuQFWangHClinical implications of plasma Epstein-Barr virus DNA in early-stage extranodal nasal-type NK/T-cell lymphoma patients receiving primary radiotherapyBlood2012120102003201022826562
   PubMed Web of Science ®Google Scholar
• ChenYZhengXChenBThe clinical significance of Epstein-Barr virus DNA in peripheral blood mononuclear cells in patients with non-Hodgkin lymphomaLeuk Lymphoma201758102349235528306367
   PubMed Web of Science ®Google Scholar
• SuzukiRYamaguchiMIzutsuKProspective measurement of Epstein-Barr virus-DNA in plasma and peripheral blood mononuclear cells of extranodal NK/T-cell lymphoma, nasal typeBlood2011118236018602221984805
   PubMed Web of Science ®Google Scholar
• KimHSRyuKJKoYHMacrophage inflammatory protein 1 alpha (MIP-1α) may be associated with poor outcome in patients with extran-odal NK/T-cell lymphomaHematol Oncol201735331031626928433
   PubMed Web of Science ®Google Scholar
• KimHSKimKHKimKHWhole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphomaLeuk Lymphoma200950575776319330658
   PubMed Web of Science ®Google Scholar
• WangLWangHWangJHPost-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginaseOncotarget2015630303173032626210287
   PubMed Web of Science ®Google Scholar
• MoherDLiberatiATetzlaffJAltmanDGReprint – preferred reporting items for systematic reviews and meta-analyses: the PRISMA statementPhys Ther200989987388019723669
   PubMed Web of Science ®Google Scholar
• MoherDLiberatiATetzlaffJAltmanDGPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementInt J Surg20108533634120171303
   PubMed Web of Science ®Google Scholar
• RoystonPParmarMKRestricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcomeBMC Med Res Methodol20131315224314264
   PubMed Web of Science ®Google Scholar
• ParmarMKTorriVStewartLExtracting summary statistics to perform meta-analyses of the published literature for survival endpointsStat Med19981724281528349921604
   PubMed Web of Science ®Google Scholar
• StangACritical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEur J Epidemiol201025960360520652370
   PubMed Web of Science ®Google Scholar
• TierneyJFStewartLAGhersiDBurdettSSydesMRPractical methods for incorporating summary time-to-event data into meta-analysisTrials200781617555582
   PubMed Web of Science ®Google Scholar
• HigginsJPThompsonSGQuantifying heterogeneity in a meta-analysisStat Med20022111153912111919
   PubMed Web of Science ®Google Scholar
• HigginsJPThompsonSGDeeksJJAltmanDGMeasuring inconsistency in meta-analysesBMJ2003327741455756012958120
   PubMed Web of Science ®Google Scholar
• KanakryJAHegdeAMDurandCMThe clinical significance of EBV DNA in the plasma and peripheral blood mononuclear cells of patients with or without EBV diseasesBlood201612716200726744460
   PubMed Web of Science ®Google Scholar
• KimSJYoonDHJaccardAA prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysisLancet Oncol201617338926873565
   PubMed Web of Science ®Google Scholar
• TseEKwongYLThe diagnosis and management of NK/T-cell lymphomasJ Hematol Oncol20171018528410601
   PubMed Web of Science ®Google Scholar
• KwongYLPangAWLeungAYChimCSTseEQuantification of circulating Epstein-Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significanceLeukemia201428486587023842425
   PubMed Web of Science ®Google Scholar
• YamaguchiMKitaKMiwaHFrequent expression of P-glyco-protein/MDR1 by nasal T-cell lymphoma cellsCancer1995761123518635042
   PubMed Web of Science ®Google Scholar
• KimWSSongSYAhnYCCHOP followed by involved field radiation: is it optimal for localized nasal natural killer/T-cell lymphoma?Ann Oncol200112334935211332147
   PubMed Web of Science ®Google Scholar
• LeeSHAhnYCKimWSKoYHKimKParkKThe effect of pre-irradiation dose intense CHOP on anthracyline resistance in localized nasal NK/T-cell lymphomaHaematologica200691342742816503553
   PubMed Web of Science ®Google Scholar
• HaverkosBMPanZGruAAExtranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): an update on epidemiology, clinical presentation, and natural history in North American and European casesCurr Hematol Malig Rep201611651427778143
   PubMed Web of Science ®Google Scholar